CG
CME GROUP INC. (CME)·Q1 2025 Earnings Summary
Executive Summary
- Q1 2025 delivered record revenue of $1.642B (+10% YoY), GAAP diluted EPS of $2.62, and adjusted EPS of $2.80, driven by record ADV of 29.8M contracts and record market data revenue ($195M) .
- Versus S&P Global consensus, CME posted a slight miss: revenue $1.642B vs $1.662B estimate*, and diluted EPS $2.80 vs $2.809 estimate*; EBITDA was in line ($1.190B actual vs $1.191B estimate*) — modest negatives that could temper near-term stock reaction. Values retrieved from S&P Global.
- Management emphasized robust demand across asset classes (commodities +19%, financials +12%) and record international ADV (8.8M, +19% YoY), sustaining high operating leverage (adjusted operating margin 71.1%) .
- 2025 guidance (set in Q4) remains intact: adjusted OpEx ex-license ~$1.65B; capex ~$90M; adjusted tax rate 22.5%-23.5%; fee changes and new 30% soft minimum cash collateral could add ~2%-2.5% to pretax income .
- Catalysts: sale of OSTTRA JV (~$3.1B total proceeds, CME’s 50% share; expected close ~6 months), BrokerTec Chicago launch (Q3 2025), and ongoing mix/pricing and collateral changes; these underpin earnings quality despite small consensus misses .
What Went Well and What Went Wrong
What Went Well
- Record quarter across key P&L metrics: revenue ($1.642B), adjusted operating income (
$1.2B), adjusted net income ($1.020B), adjusted EPS ($2.80) .
Quote: “generated record revenue, adjusted operating income, adjusted net income and adjusted earnings per share for the quarter” — Terry Duffy . - Broad-based volume strength with all-time quarterly ADV records in interest rates, equities, ags, FX, and crypto; record international ADV (8.8M) with EMEA/APAC strength .
Quote: “This strong growth was broad-based… quarterly volume records in interest rates, equities, agricultural commodities and foreign exchange” — Terry Duffy . - High operating leverage with discipline on costs: adjusted operating margin 71.1% (vs 68.9% last year), adjusted tax rate 23.1%; market data revenue reached a record $195M (+11% YoY) .
What Went Wrong
- Slight consensus misses: revenue (-$19M vs estimate*), diluted EPS (-$0.009 vs estimate*) for Q1 2025; prior quarters mixed (Q3 revenue slight miss*, EPS beat; Q4 both beat*) — a modest near-term overhang. Values retrieved from S&P Global.
- Average rate per contract (RPC) drifted lower YoY to $0.686 (from $0.695 in Q1 2024) as volume tiering engaged at high volumes; management noted RPC down ~1% YoY on +13% volume growth .
- Cash fell to ~$1.6B from
$3.1B at year-end due to dividend outflows ($2.6B paid in Q1), reducing balance sheet flexibility in the near term (though capital return is a core policy) .
Financial Results
Consolidated Results vs Prior Quarters
Revenue Composition
Margins
KPIs: ADV and RPC
ADV by Asset Class (000s)
Balance Sheet Highlights
Q1 2025 YoY/Sequential
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- “Our quarterly revenue crossed $1.6 billion for the first time, and we also exceeded $1 billion in adjusted net income… This quarter highlighted the strength of our product diversity and the ability [of] customers to manage risk in times of uncertainty.” — Terry Duffy .
- “Adjusted operating margin… 71.1%… highest quarterly adjusted net income and adjusted diluted earnings per share in our history” — Lynne Fitzpatrick .
- “Quarterly international ADV… record 8.8 million… broad, sustained client demand outside the U.S.” — Julie Winkler .
- “Launch [of] BrokerTec Chicago… co-located next to our U.S. Treasury futures and options… scheduled for Q3 2025” — Michael Dennis .
Q&A Highlights
- Deleveraging dynamics and open interest: Despite margin increases, OI up ~7% YoY; pockets of ag futures OI softness offset by record options OI — “risk‑on” environment in ags .
- OSTTRA sale and capital allocation: CME to receive ~50% of ~$3.1B proceeds; close expected in ~6 months; use of proceeds TBD closer to closing .
- Collateral mix after surcharge: Q1 averages $79B cash/$173B noncash; April month-to-date cash ~$131B, noncash ~$140B; majority meeting 30% soft minimum .
- International growth drivers: Double-digit growth across asset classes, strong commercial participation (+~30%), record non-U.S. options; EMEA/APAC buy-side strength .
- Energy complex momentum: Multi-year share leadership in WTI/Henry Hub; options outperformance; global benchmark adoption and record OI .
- Expenses & cloud: Q1 Google spend just under $20M (tech ~$19M, prof svcs < $1M); expect ramp through year as apps migrate .
Estimates Context
Notes: Values retrieved from S&P Global.
Interpretation: Q4 2024 was a beat on both revenue and EPS; Q3 was a slight revenue miss but adjusted EPS beat; Q1 2025 was a modest miss on revenue and diluted EPS relative to consensus*.
Key Takeaways for Investors
- Underlying demand remains robust across asset classes and geographies, with record ADV and pricing/fee levers sustaining high margins despite slight Q1 consensus misses .
- Watch evolving collateral mix and the 30% soft minimum in cash; early April data suggests rising cash balances, which can boost non‑operating income or other revenue and modestly lift pretax earnings .
- Energy and ag complexes are seeing secular adoption internationally (Henry Hub/WTI, grains), with options as a key growth vector — supportive of revenue quality and RPC mix over 2025 .
- International growth supports tax-rate benefits and diversification; management is leaning into co‑located cash/futures infrastructure (BrokerTec Chicago) to deepen the rates moat .
- The OSTTRA monetization and buyback authorization increase flexibility for capital returns or strategic investments; timing and use of proceeds are near‑term watch items .
- Expect continued OpEx discipline with cloud migration investments; margin profile likely remains structurally high given operating leverage and fee/tiering strategies .
- Near-term narrative: Slight miss vs consensus* but strong volume/mix, expanding international footprint, and operational resiliency (margin management, cross‑margining) should anchor the medium‑term thesis.